- Home
- FCO vs VERU Comparison
FCO vs VERU Comparison
Compare FCO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- VERU
- Stock Information
- Founded
- FCO 1991
- VERU 1971
- Country
- FCO United Kingdom
- VERU United States
- Employees
- FCO N/A
- VERU N/A
- Industry
- FCO Investment Managers
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- VERU Health Care
- Exchange
- FCO Nasdaq
- VERU Nasdaq
- Market Cap
- FCO 85.6M
- VERU 85.5M
- IPO Year
- FCO N/A
- VERU 1990
- Fundamental
- Price
- FCO $6.67
- VERU $3.52
- Analyst Decision
- FCO
- VERU Strong Buy
- Analyst Count
- FCO 0
- VERU 3
- Target Price
- FCO N/A
- VERU $33.33
- AVG Volume (30 Days)
- FCO 100.1K
- VERU 227.6K
- Earning Date
- FCO 01-01-0001
- VERU 08-12-2025
- Dividend Yield
- FCO 14.96%
- VERU N/A
- EPS Growth
- FCO N/A
- VERU N/A
- EPS
- FCO 0.43
- VERU N/A
- Revenue
- FCO N/A
- VERU $16,886,419.00
- Revenue This Year
- FCO N/A
- VERU N/A
- Revenue Next Year
- FCO N/A
- VERU N/A
- P/E Ratio
- FCO $12.30
- VERU N/A
- Revenue Growth
- FCO N/A
- VERU 337.24
- 52 Week Low
- FCO $4.73
- VERU $2.64
- 52 Week High
- FCO $6.63
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- FCO 57.80
- VERU 35.24
- Support Level
- FCO $6.66
- VERU $2.64
- Resistance Level
- FCO $6.69
- VERU $3.69
- Average True Range (ATR)
- FCO 0.06
- VERU 0.39
- MACD
- FCO 0.00
- VERU 0.02
- Stochastic Oscillator
- FCO 70.23
- VERU 40.27
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.